128 related articles for article (PubMed ID: 14678365)
1. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.
Akaza H
BJU Int; 2004 Jan; 93(1):42-6. PubMed ID: 14678365
[TBL] [Abstract][Full Text] [Related]
2. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.
See WA
Curr Treat Options Oncol; 2003 Oct; 4(5):351-62. PubMed ID: 12941195
[TBL] [Abstract][Full Text] [Related]
4. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
Samant RS; Dunscombe PB; Roberts GH
Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
[TBL] [Abstract][Full Text] [Related]
5. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
Bolla M; de Reijke TM; Zurlo A; Collette L
Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
[No Abstract] [Full Text] [Related]
8. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
Souhami L; Bae K; Pilepich M; Sandler H
J Clin Oncol; 2009 May; 27(13):2137-43. PubMed ID: 19307511
[TBL] [Abstract][Full Text] [Related]
9. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer.
D'Amico AV
Urology; 2002 Sep; 60(3 Suppl 1):32-7; discussion 37-8. PubMed ID: 12231043
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
12. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.
Kaisary AV
Prostate Cancer Prostatic Dis; 2005; 8(2):140-51. PubMed ID: 15852051
[TBL] [Abstract][Full Text] [Related]
14. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.
Horwitz EM; Winter K; Hanks GE; Lawton CA; Russell AH; Machtay M
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):947-56. PubMed ID: 11240235
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85-31)].
Hinkelbein W
Strahlenther Onkol; 1998 Jul; 174(7):385-6. PubMed ID: 9689964
[No Abstract] [Full Text] [Related]
16. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant and neoadjuvant drug therapy for prostate cancer].
Miller K; Lein M; Schostak M; Schrader M
Urologe A; 2008 Nov; 47(11):1460-4. PubMed ID: 18813902
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant hormonal treatment and radiotherapy for prostate cancer.
Wachter S; Wachter-Gerstner N; Pötter R
Oncology; 2003; 65 Suppl 1():29-33. PubMed ID: 12949431
[TBL] [Abstract][Full Text] [Related]
19. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
[No Abstract] [Full Text] [Related]
20. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
